Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

Aung Pyae Phyo; Podjanee Jittamala; François H Nosten; Sasithon Pukrittayakamee; Mallika Imwong; Nicholas J White; Stephan Duparc; Fiona Macintyre; Mark Baker; Jörg J Möhrle

doi:10.1016/s1473-3099(15)00320-5

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(15)00320-5 ◽

2016 ◽

Vol 16 (1) ◽

pp. 61-69 ◽

Cited By ~ 95

Author(s):

Aung Pyae Phyo ◽

Podjanee Jittamala ◽

François H Nosten ◽

Sasithon Pukrittayakamee ◽

Mallika Imwong ◽

...

Keyword(s):

Plasmodium Falciparum ◽

Plasmodium Vivax ◽

Vivax Malaria ◽

Antimalarial Activity ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Plasmodium Vivax Malaria ◽

Open Label Phase

Download Full-text

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

The Lancet Child & Adolescent Health ◽

10.1016/s2352-4642(21)00328-x ◽

2021 ◽

Cited By ~ 1

Author(s):

Iván D Vélez ◽

Tran T Hien ◽

Justin A Green ◽

Ana Martin ◽

Hema Sharma ◽

...

Keyword(s):

Plasmodium Vivax ◽

Exposure Assessment ◽

Relapse Prevention ◽

Vivax Malaria ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Plasmodium Vivax Malaria

Download Full-text

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30309-8 ◽

2018 ◽

Vol 18 (8) ◽

pp. 874-883 ◽

Cited By ~ 35

Author(s):

Alejandro Llanos-Cuentas ◽

Martin Casapia ◽

Raúl Chuquiyauri ◽

Juan-Carlos Hinojosa ◽

Nicola Kerr ◽

...

Keyword(s):

Plasmodium Falciparum ◽

Single Dose ◽

Vivax Malaria ◽

Malaria Infection ◽

Antimalarial Activity ◽

Dihydroorotate Dehydrogenase ◽

Proof Of Concept ◽

Open Label ◽

Plasmodium Vivax Malaria ◽

Open Label Phase

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Cited By ~ 1

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

Patients with Plasmodium falciparum Malaria and Plasmodium vivax Malaria Show Increased Nitrite and Nitrate Plasma Levels

The Journal of Infectious Diseases ◽

10.1093/infdis/169.6.1418 ◽

1994 ◽

Vol 169 (6) ◽

pp. 1418-1419 ◽

Cited By ~ 40

Author(s):

A. K. Nussler ◽

W. Eling ◽

P. G. Kremsner

Keyword(s):

Plasmodium Falciparum ◽

Plasmodium Vivax ◽

Falciparum Malaria ◽

Plasma Levels ◽

Vivax Malaria ◽

Plasmodium Falciparum Malaria ◽

Plasmodium Vivax Malaria

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Download Full-text

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30480-8 ◽

2019 ◽

Vol 19 (1) ◽

pp. 46-55 ◽

Cited By ~ 9

Author(s):

Jung-Kyu Lee ◽

Ji Yeon Lee ◽

Deog Kyeom Kim ◽

Ho Il Yoon ◽

Ina Jeong ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Phase 2 ◽

Open Label ◽

Intensive Phase ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30170-9 ◽

2017 ◽

Vol 4 (10) ◽

pp. e487-e496 ◽

Cited By ~ 7

Author(s):

Fei-Er Feng ◽

Ru Feng ◽

Min Wang ◽

Jia-Min Zhang ◽

Hao Jiang ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase

Download Full-text